SCHEMBL31360840

SCHEMBL31360840

CN(CC12CC(NC(=O)OCc3ccccc3)(C1)C2)C(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
CTSL P07711 4/20 0.39
CTSB P07858 3/20 0.39
CTSS P25774 3/20 0.39
KCNA5 P22460 1/20 0.39
LMNA P02545 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
BACE1 P56817 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CTSK P43235 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
AKT1 P31749 2/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31360744 0.85 ALDH1A1 (0.43) SMN1; SMN2CTSLCTSBCTSSLMNA
SCHEMBL31360816 0.84 CTSL (0.45) SMN1; SMN2CTSLCTSBCTSSLMNA
SCHEMBL27231928 0.82 SYK (0.53) SYKSMN1; SMN2CTSLCTSBCTSS
SCHEMBL31360833 0.78 SMN1; SMN2 (0.44) SYKSMN1; SMN2CTSLCTSBCTSS
SCHEMBL31454371 0.78 SYK (0.53) SYKSMN1; SMN2CTSLCTSBCTSS
SCHEMBL6130358 0.77 SYK (0.48) SYKSMN1; SMN2CTSLCTSBCTSS
SCHEMBL29899382 0.76 LMNA (0.47) SMN1; SMN2CTSLCTSBCTSSLMNA
SCHEMBL22585249 0.76 LMNA (0.47) SMN1; SMN2CTSLCTSBCTSSLMNA
SCHEMBL10152374 0.75 SYK (0.48) SYKSMN1; SMN2CTSLCTSBCTSS
SCHEMBL31443306 0.75 CA12 (0.44) SMN1; SMN2CTSLCTSBCTSSLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747255-A1 MODULATORS OF THE ADENOSINE A2A AND A2B RECEPTOR Ryvu Therapeutics S.A. (PL) 2026-05-27 EP disclosed
WO-2025018901-A1 MODULATORS OF THE ADENOSINE A2A AND A2B RECEPTOR Ryvu Therapeutics S.A. (PL) 2025-01-23 WO disclosed